

Cell-Vive™ GMP Recombinant Human EGF (carrier-free)

Catalog# / Size 585514 / 25 μg

585516 / 100 µg

Other Names Urogastrone (URG), HOMG4

Description Epidermal growth factor (EGF) is a small 6 kD polypeptide and has six conserved cysteine

residues that form three intramolecular disulfide bonds. Human and mouse EGF share 70% homology in amino acid structure. Human EGF is synthesized as a transmembrane precursor protein (1207 amino acids) which is proteolytically cleaved to generate the 54 amino acid mature EGF. Many different cells including mammary gland cells, macrophages, gut epithelial cells, and cells in the nervous system and the kidney can produce EGF. EGF plays important roles in the regulation of cell survival, proliferation, and differentiation by binding to its receptor EGFR. For example, EGF can stimulate the proliferation of mouse embryonic stem cells or induce the terminal differentiation/growth inhibition of A431 cells. The binding of EGF to EGFR will induce receptor dimerization, which is required for activating the tyrosine kinase in the receptor cytoplasmic domain. In addition, the binding of EGF to its receptor triggers several signal transduction pathways including JAK/STAT, Ras/ERK, and PI3K/AKT pathways. Blocking of the EGF/EGFR pathway can suppress some tumor cell's proliferation. Other members of the EGF family (including transforming growth factor-α (TGF-α), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), and epigen also bind to

EGFR.

Quality Statement

BioLegend Cell-Vive™ GMP Recombinant proteins are manufactured and tested in accordance with USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Ph. Eur. Chapter 5.2.12 in a dedicated GMP facility compliant with ISO 13485:2016. Specifications and processes include:

- Low endotoxin level (≤0.1 EU/μg)
- Purity (≥ 95% or higher)
- · Bioburden testing
- Mycoplasma testing
- · Batch-to-batch consistency
- Vendor qualification
- Raw material traceability and documentation
- Documented procedures and employee training
- Equipment maintenance and monitoring records
- Lot-specific certificates of analysis
- Quality audits per ISO 13485:2016
- · QA review of released products

Product Details

Source Human EGF, 54 amino acids Asn971-Arg1023 with an N-terminal Met (Accession# P01133) was

expressed in E. coli.

Molecular Mass The 54 amino acid recombinant protein has a predicted molecular mass of approximately 6 kD. The

DTT-reduced protein migrates at approximately 6 kD and non-reduced protein migrates at

approximately 13 kD by SDS-PAGE. The N-terminal amino acid is Methionine.

Purity ≥98%, as determined by Coomassie stained SDS-PAGE.

Formulation 0.22 μm filtered protein solution is in PBS

Endotoxin Level Less than or equal to 0.1 EU per µg of protein as determined by the LAL method.

Concentration 25 μg and 100 μg sizes are bottled at 0.5 mg/mL

Storage & Handling Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at - 20°C for up to six months,

or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week or stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.

Activity Human EGF inhibits the proliferation of human epithelial A431 cells in a dose-dependent manner. The

 ED_{50} for this effect is 0.3 - 2.0 ng/mL. Human EGF induces the proliferation of NIH/3T3 cells in a dose-

dependent manner. The ED_{50} for this effect is 0.025-0.125 ng/mL.

Application

<u>Bioassay</u>

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Application References

(PubMed link indicates BioLegend citation)

- 1. Henson ES and Gibson SB. 2006. Cell Signal. 18:2089.
- 2. Burgess AW, et al. 2003. Mol. Cell. 12:541.
- 3. Imai Y, et al. 1982. Cancer Res. 42:4394.
- 4. Barnes DW. 1982. J. Cell. Biol. 93:1.
- 5. Heo JS, et al. 2006. Am. J. Physiol. Cell. Physiol. 290:C123.

Disclaimer

BioLegend Cell-Vive™ GMP Recombinant proteins are for research use only. Suitable for *ex vivo* cell processing. Not for injection or diagnostic or therapeutic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

Antigen Details

Bioactivity

Human EGF inhibits the proliferation of human epithelial A431 cells in a dose-dependent manner. The ED_{50} for this effect is 0.3 - 2.0 ng/mL. Human EGF induces the proliferation of NIH/3T3 cells in a dose-dependent manner. The ED_{50} for this effect is 0.025 – 0.125 ng/mL.

Cell Sources

Mammary gland cells, macrophages, gut epithelial cells, cells in the nervous system, and kidney

Receptors

EGFR

Antigen References

- 1. Arshad N, et al. 2018. J Biol Chem. 293:9555. PubMed
- 2. Tam A, et al. 2019. Sci Rep. 9:3353. PubMed


Regulation

EGF is a potent mitogen for many cells in culture, and *in vivo*, it induces the proliferation and differentiation of skin, cornea, lung, and trachea, among other tissues. Processing of pro EGF to mature EGF in different tissues is not equally efficient. The precursor is processed to mature EGF in the submaxillary gland, pancreas, small intestine, and mammary gland. In the submaxillary gland, EGF is fully processed, stored at secretory granules, and secreted in saliva. In kidney, EGF is present in unprocessed or intermediated forms on the cell surface.


Gene ID

1950

Product Data



Inhibition of A431 cell proliferation by human EGF.



Human EGF induces the proliferation of NIH/3T3 cells in a dose-dependent manner.

For Research Use Only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use.

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user's intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587